A cross-sectional study of 94 patients links visually assessed putaminal MRI markers to contralateral parkinsonian motor ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" clinical trials has been added to ...

Multiple system atrophy Parkinsonian type (MSA-P) is a rare neurodegenerative disease that progresses over time. It can cause problems with movement and coordination, digestion, bladder control, ...

Multiple system atrophy (MSA) is a fatal, rapidly progressive atypical parkinsonism that responds poorly to Parkinson’s disease (PD) medications, and diagnostic precision remains a critical unmet need ...

It has been quite a while since my last post. As for what happened since then, in mid-September, my husband officially ...

Multiple system atrophy (MSA) is a rare, progressive neurodegenerative disorder with high mortality and diagnostic uncertainty. We re-evaluated 80 cases from the Catalan MSA Registry (CMSAR), applying ...

The growth of the MSA market is attributed to the increasing research and developmental activities to develop disease modifying therapies for MSA. For instance, in 2020, Neuraly raised $15 million in ...

Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous system, balance, and the ability to move. The disease in many ways resembles ...

According to the study, Amprion's α-synuclein skin SAA successfully differentiated specimens from patients with MSA versus neuronal synuclein disease (NSD) while demonstrating strong agreement with ...

The presentation is available on the Alterity Therapeutics website here.